Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
- The “graying” of infertility services: an impending revolution nobody is ready for.Reprod Biol Endocrinol. 2014; 12: 63
- 2012 Assisted reproductive technology success rates: national summary and fertility clinic reports.US Department of Health and Human Services, Washington (DC)2014
- Multivariate analysis of factors affecting probability of pregnancy and live birth with in vitro fertilization: an analysis of the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System.Fertil Steril. 2010; 94: 1410-1416
- Racial and ethnic disparities in assisted reproductive technology (ART) outcomes in the United States.Fertil Steril. 2010; 93: 382-390
- Pregnancy outcomes decline in recipients over age 44: an analysis of 27,959 fresh donor oocyte in vitro fertilization cycles from the Society for Assisted Reproductive Technology.Fertil Steril. 2014; 101: 1331-1336
- Cumulative birth rates with linked assisted reproductive technology cycles.N Engl J Med. 2012; 366: 2483-2491
- Trends and outcomes for donor oocyte cycles in the United States, 2000-2010.JAMA. 2013; 310: 2426-2434
- Trends and outcomes of gestational surrogacy in the United States.Fertil Steril. 2016; 106: 435-442.e2
- Putting ‘family’ back in family planning.Hum Reprod. 2015; 30: 16-19
- Ovarian reserve screening prior to contraception?.Reprod Biomed Online. 2014; 29: 527-529
- Outcomes of fresh and cryopreserved oocyte donation.JAMA. 2015; 314: 623-624
- Fresh versus cryopreserved oocyte donation.Curr Opin Endocrinol Diabetes Obes. 2016; 23: 451-457
- Repetitive oocyte donation: a committee opinion.Fertil Steril. 2014; 102: 964-966
- Informing offspring of their conception by gamete or embryo donation: a committee opinion.Fertil Steril. 2013; 100: 45-49
Supported by intramural funds from the Center for Human Reproduction and by grants from The Foundation for Reproductive Medicine . VAK previously served as a consultant to the Centers for Disease Control and Prevention; the Center for Human Reproduction annually routinely reports in vitro fertilization outcome data to the Center for Disease Control and Prevention and Society for Assisted Reproductive Technologies; NG, DHB, and VAK are listed as coowners of a number of already awarded and still pending US patents, none of which are related to the topic of this manuscript; NG is a shareholder in Fertility Nutraceuticals, LLC, and owner of the Center for Human Reproduction; NG and DHB receive patent royalties from Fertility Nutraceuticals, LLC; NG, DFA, and DHB received research support, travel funding, and lecture fees from various Pharma and medical device companies, none of which in any way related to this manuscript.
Remaining authors report no conflict of interest.
Cite this article as: Kushnir VA, Darmon SK, Shapiro AJ, et al. Utilization of third-party in vitro fertilization in the United States. Am J Obstet Gynecol 2017;216:266.e1-10.